Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2023)
Inhibikase Therapeutics (IKT) reported EBT Margin of 440356600.0% for Q4 2023, down 44034978036.0% year-over-year from N/an in Q4 2022, and down 7347277.94% quarter-over-quarter from 5993.38% in Q3 2023.
Inhibikase Therapeutics (IKT) EBT Margin (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of EBT Margin data on file, last reported at 440356600.0% in Q4 2023.
- EBT Margin for Q4 2023 came in at 440356600.0%, down 44034978036.0% year-over-year; the trailing twelve-month figure through Sep 2024 was 2006393700.0% (down 200638752188.0% YoY), and the FY2023 annual result was 7711.98%, up 697419.0% from the prior year.
- EBT Margin eased to 440356600.0% in Q4 2023 per IKT's latest filing, from 5993.38% in the prior quarter.
- Over five years, EBT Margin peaked at 187.4% in Q1 2021 and troughed at 440356600.0% in Q4 2023.
- A 4-year average of 27549285.01% and a median of 5660.72% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin soared 25252290 bps in 2022, then tumbled 2000000000 bps in 2023.
- A 4-year view of EBT Margin shows it stood at 708.85% in 2020, then sank by 36487 bps to 259342.54% in 2021, then jumped by 97 bps to 6819.64% in 2022, then plunged by 6457080 bps to 440356600.0% in 2023.
- Business Quant data shows IKT's EBT Margin at 440356600.0% in Q4 2023, 5993.38% in Q3 2023, and 5328.07% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -440,356,600.00% |
| Sep 30, 2023 | -5,993.38% |
| Jun 30, 2023 | -5,328.07% |
| Mar 31, 2023 | -7,307.62% |
| Dec 31, 2022 | -6,819.64% |
| Sep 30, 2022 | -61,645.36% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,081.47% |
| Dec 31, 2021 | -259,342.54% |
| Sep 30, 2021 | -1,361.26% |
| Jun 30, 2021 | -193.40% |
| Mar 31, 2021 | -187.40% |
| Dec 31, 2020 | -708.85% |
| Sep 30, 2020 | -1,779.72% |
| Jun 30, 2020 | -192.12% |
| Mar 31, 2020 | -202.17% |